654 related articles for article (PubMed ID: 28890326)
1. Taurolidine-based catheter lock regimen significantly reduces overall costs, infection, and dysfunction rates of tunneled hemodialysis catheters.
Winnicki W; Herkner H; Lorenz M; Handisurya A; Kikić Ž; Bielesz B; Schairer B; Reiter T; Eskandary F; Sunder-Plassmann G; Sengoelge G
Kidney Int; 2018 Mar; 93(3):753-760. PubMed ID: 28890326
[TBL] [Abstract][Full Text] [Related]
2. Administration of taurolidine-citrate lock solution for prevention of central venous catheter infection in adult neutropenic haematological patients: a randomised, double-blinded, placebo-controlled trial (TAURCAT).
Gudiol C; Nicolae S; Royo-Cebrecos C; Aguilar-Guisado M; Montero I; Martín-Gandul C; Perayre M; Berbel D; Encuentra M; Arnan M; Cisneros-Herreros JM; Carratalà J
Trials; 2018 May; 19(1):264. PubMed ID: 29720244
[TBL] [Abstract][Full Text] [Related]
3. Cefazolin-gentamicin versus taurolidine-citrate for the prevention of infection in tunneled central catheters in hemodialysis patients: A quasi-experimental trial.
Bueloni TNV; Marchi D; Caetano C; de Souza Cavalcante R; Mendes Amaral ML; Ponce D
Int J Infect Dis; 2019 Aug; 85():16-21. PubMed ID: 31102823
[TBL] [Abstract][Full Text] [Related]
4. A 2% taurolidine catheter lock solution prevents catheter-related bloodstream infection (CRBSI) and catheter dysfunction in hemodialysis patients.
Neusser MA; Bobe I; Hammermeister A; Wittmann U
Br J Nurs; 2021 Jul; 30(14):S24-S32. PubMed ID: 34288746
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of taurolidine/urokinase versus taurolidine/heparin as a tunneled catheter lock solution in hemodialysis patients: a prospective, randomized, controlled study.
Al-Ali F; Hamdy AF; Hamad A; Elsayed M; Zafar Iqbal Z; Elsayed A; Ibrahim R; Tolba H; Buanan H; Fawzy A
Nephrol Dial Transplant; 2018 Apr; 33(4):619-626. PubMed ID: 29106676
[TBL] [Abstract][Full Text] [Related]
6. Urokinase-containing locking solution in the prevention of dialysis catheter dysfunction: a double blind randomized controlled trial.
Bonkain F; Van Hulle F; Janssens P; Catalano C; Allamani M; Stolear JC; Vandervelde D; Libertalis M; Treille S; Couttenye MM; Dhondt A; Van Biesen W; Fils JF; Tielemans C; Wissing KM
J Vasc Access; 2017 Sep; 18(5):436-442. PubMed ID: 28623638
[TBL] [Abstract][Full Text] [Related]
7. Taurolidine-citrate-heparin lock reduces catheter-related bloodstream infections in intestinal failure patients dependent on home parenteral support: a randomized, placebo-controlled trial.
Tribler S; Brandt CF; Petersen AH; Petersen JH; Fuglsang KA; Staun M; Broebech P; Moser CE; Jeppesen PB
Am J Clin Nutr; 2017 Sep; 106(3):839-848. PubMed ID: 28793993
[No Abstract] [Full Text] [Related]
8. Clinical and economic impact of the taurolidine lock on home parenteral nutrition.
Arnoriaga Rodríguez M; Pérez de Ciriza Cordeu M; Camblor Álvarez M; Bretón Lesmes I; Motilla de la Cámara M; Velasco Gimeno C; Arhip L; García Peris P; Cuerda Compés C
Nutr Hosp; 2018 Jun; 35(4):761-766. PubMed ID: 30070861
[TBL] [Abstract][Full Text] [Related]
9. A randomized double-blind controlled trial of taurolidine-citrate catheter locks for the prevention of bacteremia in patients treated with hemodialysis.
Solomon LR; Cheesbrough JS; Ebah L; Al-Sayed T; Heap M; Millband N; Waterhouse D; Mitra S; Curry A; Saxena R; Bhat R; Schulz M; Diggle P
Am J Kidney Dis; 2010 Jun; 55(6):1060-8. PubMed ID: 20207458
[TBL] [Abstract][Full Text] [Related]
10. Comparison of heparin to citrate as a catheter locking solution for non-tunneled central venous hemodialysis catheters in patients requiring renal replacement therapy for acute renal failure (VERROU-REA study): study protocol for a randomized controlled trial.
Bruyère R; Soudry-Faure A; Capellier G; Binquet C; Nadji A; Torner S; Blasco G; Yannaraki M; Barbar SD; Quenot JP
Trials; 2014 Nov; 15():449. PubMed ID: 25409678
[TBL] [Abstract][Full Text] [Related]
11. Prevention of dialysis catheter-related sepsis with a citrate-taurolidine-containing lock solution.
Betjes MG; van Agteren M
Nephrol Dial Transplant; 2004 Jun; 19(6):1546-51. PubMed ID: 14993498
[TBL] [Abstract][Full Text] [Related]
12. Significant reduction in central venous catheter-related bloodstream infections in children on HPN after starting treatment with taurolidine line lock.
Chu HP; Brind J; Tomar R; Hill S
J Pediatr Gastroenterol Nutr; 2012 Oct; 55(4):403-7. PubMed ID: 22595973
[TBL] [Abstract][Full Text] [Related]
13. Prevention of tunneled cuffed catheter dysfunction with prophylactic use of a taurolidine urokinase lock: A randomized double-blind trial.
Bonkain F; Stolear JC; Catalano C; Vandervelde D; Treille S; Couttenye MM; Dhondt A; Libertalis M; Allamani M; Madhoun P; Van Craenenbroeck AH; Vanommeslaeghe F; Van Hulle F; Durieux P; Van Limberghen I; Tielemans C; Wissing KM
PLoS One; 2021; 16(5):e0251793. PubMed ID: 34015014
[TBL] [Abstract][Full Text] [Related]
14. Comparative effectiveness of two catheter locking solutions to reduce catheter-related bloodstream infection in hemodialysis patients.
Moore CL; Besarab A; Ajluni M; Soi V; Peterson EL; Johnson LE; Zervos MJ; Adams E; Yee J
Clin J Am Soc Nephrol; 2014 Jul; 9(7):1232-9. PubMed ID: 24970874
[TBL] [Abstract][Full Text] [Related]
15. Observational study of need for thrombolytic therapy and incidence of bacteremia using taurolidine-citrate-heparin, taurolidine-citrate and heparin catheter locks in patients treated with hemodialysis.
Solomon LR; Cheesbrough JS; Bhargava R; Mitsides N; Heap M; Green G; Diggle P
Semin Dial; 2012; 25(2):233-8. PubMed ID: 21916999
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of taurolidine on the prevention of catheter-related bloodstream infections in patients on home parenteral nutrition.
Al-Amin AH; Sarveswaran J; Wood JM; Burke DA; Donnellan CF
J Vasc Access; 2013; 14(4):379-82. PubMed ID: 23817948
[TBL] [Abstract][Full Text] [Related]
17. Impact of locking solutions on conditioning biofilm formation in tunnelled haemodialysis catheters and inflammatory response activation.
Jiménez Hernández M; Soriano A; Filella X; Calvo M; Coll E; Rebled JM; Poch E; Graterol F; Compte MT; Maduell F; Fontsere N
J Vasc Access; 2021 May; 22(3):370-379. PubMed ID: 32691665
[TBL] [Abstract][Full Text] [Related]
18. Taurolidine lock in home parenteral nutrition in adults: results from an open-label randomized controlled clinical trial.
Klek S; Szczepanek K; Hermanowicz A; Galas A
JPEN J Parenter Enteral Nutr; 2015 Mar; 39(3):331-5. PubMed ID: 24604029
[TBL] [Abstract][Full Text] [Related]
19. Tegaderm™ CHG dressing significantly improves catheter-related infection rate in hemodialysis patients.
Righetti M; Palmieri N; Bracchi O; Prencipe M; Bruschetta E; Colombo F; Brenna I; Stefani F; Amar K; Scalia A; Conte F
J Vasc Access; 2016 Sep; 17(5):417-422. PubMed ID: 27516139
[TBL] [Abstract][Full Text] [Related]
20. Randomized controlled trial of taurolidine citrate versus heparin as catheter lock solution in paediatric patients with haematological malignancies.
Dümichen MJ; Seeger K; Lode HN; Kühl JS; Ebell W; Degenhardt P; Singer M; Geffers C; Querfeld U
J Hosp Infect; 2012 Apr; 80(4):304-9. PubMed ID: 22342714
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
